Shares of Hims & Hers tumble 26% after FDA says semaglutide is no longer in shortage

Category: Health

Shares of Hims & Hers Health fell 26% after the FDA announced the resolution of the semaglutide injection shortage. Semaglutide is the key ingredient in popular weight loss and diabetes drugs, leading to increased demand for compounded alternatives from digital health companies like Hims & Hers. Compounded drugs are custom-made and typically cheaper than brand-name options, with Hims & Hers offering semaglutide for under $200 per month compared to around $1,000 for branded versions.

Keywords: Hims & Hers Health, semaglutide, compounded medications

Source: CNBC

Update At: 2/22/2025

Related Sources